Masoud Azodi Selected Research

hI-con1

10/2011	Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
6/2011	Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masoud Azodi Research Topics

Disease

65	Neoplasms (Cancer) 04/2024 - 05/2005
32	Ovarian Neoplasms (Ovarian Cancer) 09/2023 - 05/2005
31	Carcinoma (Carcinomatosis) 12/2023 - 09/2005
13	Ovarian Epithelial Carcinoma 09/2023 - 08/2005
11	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 03/2014
9	Carcinosarcoma 01/2023 - 02/2008
8	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020 - 07/2009
5	Adenocarcinoma 01/2021 - 06/2011
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2019 - 11/2005
4	Ovarian Diseases (Ovarian Disease) 12/2015 - 07/2009
3	Disease Progression 10/2021 - 05/2011
3	Hypersensitivity (Allergy) 12/2018 - 10/2006
3	Ascites 01/2016 - 08/2009
3	Neoplasm Metastasis (Metastasis) 12/2013 - 02/2009
2	Infections 10/2023 - 07/2009
2	Hemorrhage 01/2019 - 03/2015
2	Uterine Neoplasms (Uterine Cancer) 01/2018 - 01/2015
2	Lacerations 10/2016 - 07/2015
2	Papillary Carcinoma 01/2016 - 01/2010
2	Bites and Stings (Sting) 01/2016 - 02/2015
2	Wounds and Injuries (Trauma) 07/2015 - 03/2015
2	Neutropenia 06/2015 - 03/2014
2	Hypoxia (Hypoxemia) 06/2015 - 01/2014
2	Leiomyoma (Uterine Fibroids) 05/2015 - 04/2015

Drug/Important Bio-Agent (IBA)

13	PlatinumIBA 03/2024 - 09/2005
12	Immunoconjugates (Immunoconjugate)IBA 12/2023 - 10/2014
11	Paclitaxel (Taxol)FDA LinkGeneric 10/2021 - 12/2006
10	Carboplatin (JM8)FDA LinkGeneric 10/2021 - 10/2006
8	Proteins (Proteins, Gene)FDA Link 10/2018 - 02/2009
7	Trastuzumab (Herceptin)FDA Link 11/2021 - 09/2015
7	Epithelial Cell Adhesion MoleculeIBA 01/2016 - 07/2009
6	Monoclonal AntibodiesIBA 10/2018 - 07/2009
5	neratinibIBA 01/2023 - 10/2015
5	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2014
5	sacituzumab govitecanIBA 02/2020 - 01/2020
5	Messenger RNA (mRNA)IBA 12/2011 - 05/2005
4	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 02/2013
4	ixabepilone (BMS 247550)FDA Link 03/2024 - 07/2013
4	olaparibIBA 01/2023 - 10/2019
4	taxaneIBA 01/2022 - 05/2011
4	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2020 - 12/2010
4	Interleukin-2 (IL2)IBA 12/2011 - 12/2010
3	AfatinibIBA 04/2024 - 01/2019
3	Bevacizumab (Avastin)FDA Link 03/2024 - 06/2015
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 12/2018
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023 - 10/2019
3	EpitopesIBA 11/2021 - 01/2009
3	ParaffinIBA 01/2020 - 11/2011
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2020
3	Surface Antigens (Surface Antigen)IBA 01/2020 - 01/2020
3	DuocarmycinsIBA 10/2017 - 01/2016
3	trastuzumab duocarmazineIBA 10/2017 - 01/2016
3	Clostridium enterotoxinIBA 01/2017 - 12/2011
3	Claudin-3IBA 01/2017 - 12/2011
3	SolitomabIBA 01/2016 - 02/2015
3	CytokinesIBA 01/2016 - 12/2006
3	Peptides (Polypeptides)IBA 12/2015 - 01/2009
3	Small Interfering RNA (siRNA)IBA 12/2011 - 09/2011
3	Macrophage Colony-Stimulating FactorIBA 09/2011 - 05/2005
3	RNA (Ribonucleic Acid)IBA 09/2011 - 07/2009
3	adecatumumabIBA 12/2010 - 01/2010
2	copanlisibIBA 04/2024 - 11/2019
2	VaccinesIBA 04/2024 - 07/2009
2	Topoisomerase I InhibitorsIBA 12/2023 - 01/2023
2	trastuzumab deruxtecanIBA 12/2023 - 01/2023
2	Cisplatin (Platino)FDA LinkGeneric 09/2023 - 05/2011
2	niraparibIBA 11/2022 - 01/2019
2	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 01/2022 - 10/2019
2	Adenosine Diphosphate (ADP)IBA 01/2022 - 10/2019
2	pertuzumabIBA 11/2021 - 10/2017
2	Opioid Analgesics (Opioids)IBA 11/2020 - 07/2020
2	Formaldehyde (Formol)FDA Link 01/2020 - 01/2020
2	Oral ContraceptivesIBA 01/2019 - 09/2011
2	Ado-Trastuzumab EmtansineIBA 10/2017 - 01/2017
2	HLA-DR Antigens (HLA-DR)IBA 01/2016 - 10/2015
2	ChromiumIBA 01/2016 - 02/2015
2	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 10/2015 - 07/2015
2	TOR Serine-Threonine KinasesIBA 06/2015 - 03/2014
2	NucleotidesIBA 04/2015 - 02/2013
2	Topotecan (Hycamtin)FDA LinkGeneric 03/2014 - 08/2005
2	epothilone B (EPO906)IBA 01/2014 - 07/2013
2	TubulinIBA 01/2014 - 07/2013
2	A-factor (Streptomyces)IBA 10/2011 - 06/2011
2	Thromboplastin (Tissue Factor)IBA 10/2011 - 06/2011
2	hI-con1IBA 10/2011 - 06/2011
2	Interferon-gamma (Interferon, gamma)IBA 02/2009 - 01/2009
2	3' Untranslated Regions (3' UTR)IBA 02/2009 - 05/2005
1	Imiquimod (Aldara)FDA LinkGeneric 04/2024

Therapy/Procedure

30	Drug Therapy (Chemotherapy) 09/2023 - 09/2005
25	Therapeutics 04/2024 - 09/2005
9	Hysterectomy 10/2023 - 09/2005
9	Immunotherapy 12/2011 - 01/2009
4	Neoadjuvant Therapy 09/2023 - 04/2007
3	Lymph Node Excision (Lymph Node Dissection) 10/2023 - 01/2015
3	Cytoreduction Surgical Procedures 09/2023 - 04/2007
3	Intravenous Administration 02/2020 - 01/2020
3	Laparotomy 04/2019 - 07/2016
3	Brachytherapy 07/2016 - 02/2015
2	Gynecologic Surgical Procedures (Gynecologic Surgery) 07/2020 - 04/2019
2	Minimally Invasive Surgical Procedures 04/2019 - 03/2015